India Pharma - IPM Grew 23.9% In February On Favorable Base: Dolat Capital

Indian companies registered a growth of 25% while MNCs registered a growth of 17% for the month.

<div class="paragraphs"><p>Colourful capsules arranged for photograph. (Source: Joshua Coleman /Unsplash)</p></div>
Colourful capsules arranged for photograph. (Source: Joshua Coleman /Unsplash)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 

Dolat Capital Report

As per IQVIA, the India pharma market grew 23.9% YoY and 0.5% month-on-month for the month of February 2023 on account of low base in Feb-22.

As of moving annual total Feb-23 IPM grew 6.7% YoY mainly driven by price growth of 5.4% and new introduction growth of 2.3% while volume growth declined by 0.9%.

Indian companies registered a growth of 25% while multinational companies registered a growth of 17% for the month.

Sun Pharmaceutical Industries Ltd. remained at the number one position with 8% market share, followed by Abbott Ltd., Cipla Ltd., Mankind and Alkem Laboratories Ltd. making up the top five companies of the IPM.

Acute therapies increased 27% YoY in the month of Feb-23 on low base, while chronic therapies grew 19%.

Anti-infectives/respiratory therapies registered strong growth of 51%/ 55% YoY in the month of Feb-23. The highest contributing sub-groups for these therapies were Amoxicillin and Clavulanate solids in anti-infectives and cough preparation ethical in respiratory segments.

Click on the attachment to read the full report:

Dolat Capital Indian Pharma Market (IPM) Monthly Data - Feb 2023.pdf
Marksans Pharma - With Focus On Backward Integration, Operating Margin Is Expected To Improve: HDFC Securities


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.